

Medical Coverage Policy | Yescarta (axicabtagene)



EFFECTIVE DATE: 06 | 01 | 2018

POLICY LAST UPDATED: 07 | 16 | 2019

OVERVIEW

Yescarta (axicabtagene) is used in the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. It is made from the patient's own white blood cells.

This policy is applicable to BlueCHiP for Medicare products only. For Commercial Products, see related policy section

MEDICAL CRITERIA

BlueCHiP for Medicare

Yescarta (axicabtagene) will be approved when ALL of the following are met:

1. One of the following:
 - a. The patient has a diagnosis of relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (note: patient must meet all aspects of the diagnosis as indicated)
- OR**
- b. The use of the target agent is for an indication that is supported by compendia. (NCCN Compendium™ [level of evidence 1, 2A], AHFS, DrugDex [FDA approved Class I or Class IIa]), or the prescriber has submitted additional documentation (the dose is supported by clinical research in 2 or more peer reviewed medical journals) supporting the requested therapeutic use (approval by the Clinical Review Pharmacist required).

AND

2. The patient does not have primary central nervous system lymphoma
- AND**
3. The prescriber has confirmed the patient has CD19 tumor expression
- AND**
4. The patient has relapsed or has refractory large B-cell lymphoma after two or more lines of systemic therapy
- AND**
5. The patient does not have active uncontrolled infection including Hepatitis B, Hepatitis C, or HIV infection
- AND**
6. The patient does not have any FDA labeled contraindications to the requested agent
- AND**
7. The patient has not previously been treated with gene therapy including the requested agent

PRIOR AUTHORIZATION

Prior authorization is required for BlueCHiP for Medicare.

POLICY STATEMENT

BlueCHiP for Medicare

Yescarta (axicabtagene) is medically necessary when all of the criteria have been met.

Note: Blue Cross and Blue Shield of Rhode Island reserves the right to request information from the provider regarding the members response to the therapy. Failure to agree may result in denial of the request. Provider agrees to provide documentation of response upon request.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable physician administered drug benefits/coverage.

BACKGROUND

Axicabtagene is CD19-directed genetically modified autologous T cell immunotherapy. Efficacy of axicabtagene was studied in a single-arm, open-label, multicenter trial evaluated the efficacy of a single infusion of axicabtagene in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Eligible patients had refractory disease to the most recent therapy or relapse within 1 year after autologous hematopoietic stem cell transplantation (HSCT). The study excluded patients with prior allogeneic HSCT, any history of central nervous system lymphoma, ECOG performance status of 2 or greater, absolute lymphocyte count less than 100/ μ L, creatinine clearance less than 60 mL/min, hepatic transaminases more than 2.5 times the upper limit of normal, cardiac ejection fraction less than 50%, or active serious infection.

Efficacy was established based on complete remission (CR) rate and duration of response (DOR), as determined by an independent review committee. The median time to response was 0.9 months (range: 0.8 to 6.2 months). Response durations were longer in patients who achieved CR, as compared to patients with a best response of partial remission (PR) (Table 6). Of the 52 patients who achieved CR, 14 initially had stable disease (7 patients) or PR (7 patients), with a median time to improvement of 2.1 months (range: 1.6 to 5.3 months).

CODING

BlueCHiP for Medicare

Q2041 Axicabtagene Ciloleucel, up to 200 Million Autologous Anti-CD19 CAR T Cells, Including Leukapheresis And Dose Preparation Procedures, Per Infusion

RELATED POLICIES

Prior Authorization of Drugs

PUBLISHED

Provider Update, September 2019

Provider Update, June 2018

Provider Update, March 2018

REFERENCES:

1. Yescarta prescribing information. Kite Pharma, Inc. October 2017.

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

